- Home
- STTK vs ARQQ Comparison
STTK vs ARQQ Comparison
Compare STTK & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ARQQ
- Stock Information
- Founded
- STTK 2016
- ARQQ 2017
- Country
- STTK United States
- ARQQ United Kingdom
- Employees
- STTK N/A
- ARQQ N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ARQQ Computer Software: Prepackaged Software
- Sector
- STTK Health Care
- ARQQ Technology
- Exchange
- STTK Nasdaq
- ARQQ Nasdaq
- Market Cap
- STTK 59.7M
- ARQQ 50.0M
- IPO Year
- STTK 2020
- ARQQ N/A
- Fundamental
- Price
- STTK $1.24
- ARQQ $7.92
- Analyst Decision
- STTK Hold
- ARQQ Strong Buy
- Analyst Count
- STTK 3
- ARQQ 1
- Target Price
- STTK $2.00
- ARQQ $50.00
- AVG Volume (30 Days)
- STTK 357.1K
- ARQQ 229.1K
- Earning Date
- STTK 11-14-2024
- ARQQ 11-26-2024
- Dividend Yield
- STTK N/A
- ARQQ N/A
- EPS Growth
- STTK N/A
- ARQQ N/A
- EPS
- STTK N/A
- ARQQ N/A
- Revenue
- STTK $6,435,000.00
- ARQQ $740,000.00
- Revenue This Year
- STTK $115.09
- ARQQ $341.56
- Revenue Next Year
- STTK N/A
- ARQQ $274.91
- P/E Ratio
- STTK N/A
- ARQQ N/A
- Revenue Growth
- STTK 382.75
- ARQQ N/A
- 52 Week Low
- STTK $1.07
- ARQQ $3.72
- 52 Week High
- STTK $11.76
- ARQQ $23.00
- Technical
- Relative Strength Index (RSI)
- STTK 38.29
- ARQQ 56.19
- Support Level
- STTK $1.14
- ARQQ $5.72
- Resistance Level
- STTK $1.56
- ARQQ $10.68
- Average True Range (ATR)
- STTK 0.12
- ARQQ 1.12
- MACD
- STTK 0.07
- ARQQ 0.26
- Stochastic Oscillator
- STTK 24.42
- ARQQ 49.48
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology which makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. Arqit delivers its symmetric key agreement technology via its QuantumCloud. Its product, QuantumCloud, enables any device to download a lightweight software agent, which can create keys in partnership with any other device. The firm operates in one segment that is, the provision of cybersecurity services via satellite and terrestrial platforms. Key revenue comes from the UK.